- 英文名称Testosterone Cypionate
- 中文名称环戊丙酸睾酮
- IUPAC名称[(8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] 3-cyclopentylpropanoate
- 其它别名Depo-Testosterone; Testosterone cyclopentylpropionate
- CAS编号58-20-8
- MFCD编号:MFCD00053944
- EINECS号:200-368-4
- FDA UNII编号:M0XW1UBI14
- 分子式:C27H40O3
- 分子量:412.613
- 产品CID: 1557026
- 产品分类原料药 → 激素及调节内分泌功能类药 → 雄激素及同化激素类药
欧盟法规
ECHA物质ECHA物质C&L通报REACH预注册上下游产品
cyclopentanepropanoyl chloride testosterone 3-cyclopentyl-propionic acid-anhydride 3-ethoxy-17β-(3-cyclopentyl-propionyloxy)-androsta-3,5-dienetestosterone 3-Ethoxy-17β-(3-Cyclopentyl-Propionyloxy)-Androsta-3,5-Diene置于盐酸,丙酮体系中,化学反应生成 环戊丙酸睾酮
参考文献:An Improved Method Of Preparing Testosterone,Dihydrotestosterone And Some Of Their Esters
标题:An Improved Method Of Preparing Testosterone,Dihydrotestosterone And Some Of Their Esters
摘要:
DOI:10.1021/ja01099A040
海关参考信息
- 2901210000-乙烯
2901220000-丙烯
2905122000-异丙醇
2909110000-乙醚 - 💡 提示:海关信息按照顺序优先匹配,如需确认的海关信息,请参考相关资料。
- 详情请参考:📖 海关编码查询和海关进出口税则
专利信息
专利号:US-4581416-A
优先权日:1981-01-19
标题 :Process for the synthesis of tertiary phosphine oxides and sulfides, and new tertiary phosphine oxides and sulfides
发明人:BERGERET WILFRID; BOILEAU SYLVIE; GAUTIER JEAN-CLAUDE; RAYNAL SERGE
权利人:POUDRES & EXPLOSIFS STE NALE
摘要:The invention relates to processes for the synthesis of tertiary phosphine oxides and sulfides. The process according to the invention consists, in a first step, of reacting a secondary phosphine oxide or sulfide with an optionally activated alkali metal amide, and, in a second step, of reacting the mixture obtained in the first step with an organic halide containing at least one halogenophenyl radical or one halogenomethyl group. Tertiary phosphine oxides and sulfides are complexing agents of high stability.
专利号:US-8431712-B2
优先权日:2004-02-09
标 题 :Methods for the synthesis of pyridoxamine
发明人:KHALIFAH RAJA G; KEILITZ ROLAND; KOELLNER CHRISTOPH; DEGENHARDT THORSTEN; BRAND STEPHEN ROBERT
权利人:KHALIFAH RAJA G; KEILITZ ROLAND; KOELLNER CHRISTOPH; DEGENHARDT THORSTEN; BRAND STEPHEN ROBERT; NEPHROGENEX INC
摘要:The invention provides non-oxidative methods for the large scale manufacture of pyridoxamine (I) (4-aminomethyl-3-hydroxy-5-hydroxymethyl-2-methylpyridine): n nand salts thereof.n nThe invention also provides intermediate compounds for the synthesis of pyridoxamine, as well as compositions and methods for the treatment and/or prevention of conditions associated with the formation of post-Amadori advanced glycation end-products.
专利号:WO-2021224477-A1
优先权日:2020-05-08
标 题 :A method for on-surface synthesis of a hexagonal boron nitride monolayer
发明人:CUN HUANYAO; HEMMI ADRIAN; MIAO ZICHUN; ALTMANN MICHAEL SCOTT; OSTERWALDER JÜRG; GREBER THOMAS
权利人:UNIV ZUERICH; HONG KONG UNIV OF SCIENCE AND TECHNOLOGY
摘要:A method for the formation of a layer of boron nitride, especially a hexagonal boron nitride monolayer, on a substrate (300) wherein the method is characterized by the following steps: A) Providing a layer of boron nitride, especially a hexagonal boron nitride monolayer (200), on a first substrate (100); B) Delamination of the boron nitride layer (200) from the first substrate (100) and transfer of said layer (200) to a second substrate (300); C) Annealing the layer (200) on said second substrate (300) by heating to a first target temperature under formation of a first crystal structure, preferably in vacuum; D) Annealing the layer (200) on said second substrate (300) by heating to a second target temperature under formation of second crystal structure, wherein the second target temperature is higher than the first target temperature.
专利号:US-2013035307-A1
优先权日:2010-01-26
标 题:Methods for treating or preventing the spread of cancer using semi-synthetic glycosaminoglycosan ethers
发明人:PRESTWICH GLENN D; KENNEDY THOMAS P
权利人:UNIV UTAH RES FOUND; PRESTWICH GLENN D; KENNEDY THOMAS P
摘要:Described herein are methods for the treatment and prevention of tumor metastasis using alkylated and fluoroalkylated semi-synthetic glycosaminoglycan ethers (“SAGEsâ€?). The synthesis of sulfated alkylated and fluoroalkylated SAGEs is also described.
专利号:WO-7800001-A1
优先权日:1977-08-25
标 题:Low temperature synthesis of vitreous bodies and their intermediates
发明人:SAMANTA M
权利人:SAMANTA M
摘要:A method of making glass of high purity and in virtually unlimited shapes via solution deposition on a porous self-supporting body by reaction between a first solution and a second solution; an a product made thereby. The rust solution containing at least one basic glass forming solute is confined within a porous container, the walls of which are substantially impermeable to the basic solute. The second solution containing at least one acidic solute is diffused into the porous container through its walls which are substantially permeable to the said acidic solute. The reaction between the rust solution and the second solution takes place within the porous container leading to the deposition of a self-supporting porous body on the inside walls of the container. The porous body which is crystalline, vitreous or intermediate between the two, is purified by leaching and/or washing, dried and thermally consolidated, to a transparent non-porous glass.
专利号:US-12295961-B2
优先权日:2009-12-31
标 题:Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
发明人:DHINGRA OM
权利人:MARIUS PHARMACEUTICALS INC
摘要:A formulation for drug delivery, providing enhanced modulation of solubility, stability, absorption, metabolism, and/or pharmacokinetic profile of a lipophilic therapeutic agent by formulation with sterols and/or sterol esters, resulting in higher bioavailability of a therapeutic agent administered to a subject in need of such therapeutic agent. The formulation contains a therapeutic agent and a sterol or sterol ester, and can, optionally, further contain a solubilizer and/or an enhancing agent. Also described are pharmaceutical compositions containing the formulations and methods of making and methods of using the formulations and pharmaceutical compositions. Formulations of the disclosure can be constituted to minimize the synthesis of dihydrotestosterone when the therapeutic agent includes testosterone or testosterone esters.